Covered recipient · General Payments record
ELAINE S KAMIL
Allopathic & Osteopathic Physicians Pediatrics Pediatric Nephrology
General Payments · PY2018–2024
$14,900.32
- Reported across 45 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $794.58 | 3 |
| Food and Beverage | $793.67 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Retrophin, Inc. | $1,425.51 | 6 |
| Amgen Inc. | $103.59 | 1 |
| Novo Nordisk Health Care AG | $44.52 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $14.63 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $103.59 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117292208 | CMS |
| Novartis Pharmaceuticals Corporation | $14.63 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087148460 | CMS |
| Novo Nordisk Health Care AG | $44.52 | 10/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096553570 | CMS |
| Travere Therapeutics, Inc. | $405.16 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149878556 | CMS |
| Travere Therapeutics, Inc. | $458.95 | 09/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1149878561 | CMS |
| Travere Therapeutics, Inc. | $238.26 | 09/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1149878576 | CMS |
| Travere Therapeutics, Inc. | $97.37 | 10/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1149878564 | CMS |
| Travere Therapeutics, Inc. | $105.94 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149878568 | CMS |
| Travere Therapeutics, Inc. | $119.83 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149878572 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.